PMC3617978_01
a CT scan shows a solid lesion with compression of the right-side profile of VI and VIII hepatic segments attributable to recurrent disease. b After 2 courses of sunitinib treatment, a CT scan documents a change in the consistency of the lesion, which appear predominantly fluid.
cro-0006-0090-g01.jpg
PMC3617978_01_cro-0006-0090-g01.jpg
F1
The control CT scan showed a volume reduction of the lesion D9-D10 and the appearance of a solid new lesion with compression of the right-side profile of VI and VIII hepatic segments attributable to recurrent disease (fig. 1a). A CT scan performed after 2 courses of therapy showed a partial response: the lesion remained along the side profile of the right lobe, but there was no longer a recognizable solid component, the alteration was predominantly fluid (fig. 1b).
PMC3617978_02
a PET scan pretreatment showing the appearance of a new right iliac bone lesion. b PET scan after treatment documents response to sunitinib.
cro-0006-0090-g02.jpg
PMC3617978_02_cro-0006-0090-g02.jpg
F2
An 18F-FDG PET scan revealed new bony lesions (fig. 2a), and treatment with sunitinib was initiated. A PET scan performed 3 months later revealed a partial response (fig. 2b); therefore, the treatment was continued for a further 6 months with stable disease.
PMC3617978_03
a CT scan shows bilateral lung metastasis. b After 2 months of sunitinib treatment, a CT scan documents a partial response to treatment with the disappearance of some pulmonary nodules.
cro-0006-0090-g03.jpg
PMC3617978_03_cro-0006-0090-g03.jpg
F3
After this treatment, a reevaluation CT scan showed clear disease progression, involving lung (fig. 3a), mediastinal lymph nodes and bone (C7; D1-D4). After 2 months of therapy, a chest CT scan showed a partial response with the disappearance of some pulmonary nodules and a reduction in size of some others (fig. 3b).